Results 31 to 40 of about 6,532 (197)
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)
Canadian Journal of Health Technologies, 2021 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +3 more sources
Ivacaftor Inhibits Glioblastoma Stem Cell Maintenance and Tumor Progression
Frontiers in Cell and Developmental Biology, 2021 Glioblastoma (GBM) is the most common and malignant primary brain tumor. Glioblastoma stem cells (GSCs) not only initiate and sustain uncontrolled cell proliferation but also resistant to conventional clinical therapies including temozolomide (TMZ ...
Kun Liu +13 more
doaj +1 more source
, 2022 Background and purpose: Cystic fibrosis (CF) is associated with a myriad of respiratory complications including increased susceptibility to lung infections and inflammation. Progressive inflammatory insults lead to airway damage and remodeling, resulting
Andrew Jarnicki (322440) +3 more
core +2 more sources
, 2018 BACKGROUND & OBJECTIVE: Since the release of ivacaftor-lumacaftor, several red-flags have been raised that highlight the clinical efficacy of this combination strategy that may be limited due to antagonistic drug-drug interactions.
Schneider, EK
core +1 more source
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
European Respiratory Review, 2020 Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation ...
Michal Shteinberg +1 more
doaj +1 more source
Elexacaftor/Ivacaftor/Tezacaftor: First Approval
, 2019 Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding. Conflict of interest: Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article ...
Sheridan M. Hoy (4897468)
core +1 more source
The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
PLoS ONE, 2020 ImportanceSinonasal symptoms in patients suffering from cystic fibrosis can negatively influence the quality of life and sinuses can be a niche for pathogens causing infection and inflammation leading to a decrease of lung function.
Romee Gostelie +7 more
doaj +1 more source
Frontiers in Immunology, 2023 IntroductionCystic fibrosis (CF), especially CF lung disease, is characterized by chronic infection, immune dysfunction including impairment of regulatory T cells (Tregs) and an exaggerated inflammatory response.
Dirk Westhölter +9 more
doaj +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40‐item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF‐specific minimal clinically important difference (MCID) has not been ...
Eugene Oh +34 more
wiley +1 more source
Summary data for S8, R117H-5T, (±) ivacaftor.
, 2014 (A) Mean ± SEM for the final (30 min) volume of C-sweat secretion per gland (50–53 glands measured for each test) (±) ivacaftor. (B) C-sweat/M-sweat ratios expressed as percent of the WT mean. Results are means ± SEM for 49–53 glands per test.
Jessica E. Char (476386) +11 more
core +1 more source